Vitamin D supplements can help reduce the rate of moderate-to-severe COPD* exacerbations in patients with inadequate vitamin D levels (<25 nmol/L) at baseline, but not in those with higher levels, according to a meta-analysis of randomized controlled trials (RCTs).
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Researchers have recently developed a novel risk score, namely TARRACO*, based on bedside clinical variables and cardiac troponin (cTn) concentrations, which allows the precise quantification of risk for death and cardiac-related rehospitalizations at 180 days in patients with type 2 myocardial infarctions (T2MI) and myocardial injury (MI).
Total serum cholesterol is inversely associated with the risk of pancreatic cancer, with a recent study reporting a risk increase at low TSC levels and a protective effect at mildly elevated TSC levels (4–6 mmol/L).
The addition of the monoclonal antibody andecaliximab to nivolumab or a chemotherapy regimen (modified FOLFOX6*) did not provide survival benefit in patients with pretreated metastatic or untreated HER2-negative gastric/gastroesophageal (G/GEJ) adenocarcinoma, according to data presented at ASCO GI 2019.
Experts from Hong Kong are recommending cardiac evaluation of surviving relatives and next-generation sequencing (NGS) molecular autopsy as components of forensic investigations for young victims of sudden cardiac death (SCD).
New drug applications approved by US FDA as of 01- 15 February 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Liraglutide was as effective as a structured supervised lifestyle modification programme combining diet and exercise for reducing weight, liver damage, and liver fat at 26 weeks in obese Asians with nonalcoholic fatty liver disease (NAFLD), a study shows.
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.